Atizoram (CP-80633) is a phosphodiesterase IV inhibitor with bronchodilatory and antiinflammatory properties. It was in phase II trials with Pfizer in the US for the treatment of asthma, atopic dermatitis and psoriasis. Development of atizoram has been discontinued in the asthma indication and no recent development has been reported for the other indications. CP-80633 inhibits PDE4 isozymes (human lung IC50 = 1.27 uM) in the absence of effects on PDE1, PDE2, PDE3 and PDE5 isozymes (IC50 > 100 uM). It exhibits no significant selectivity for any single cloned PDE4A, B, C or D isoform.

Butoprozine increased the action potential duration like amiodarone, depressed the plateau phase like verapamil and decreased the amplitude and the maximum rate of depolarization. Butoprozine injected intravenously depressed sino-atrial node function, lengthened A-V nodal conduction time and the A-V nodal refractory period, and prolonged the atrial refractory period. Thus butoprozine acted preferentially on parts of the myocardial tissue where the slow inward current seems to be particularly involved. In this respect, butoprozine was more active than amiodarone, but in contrast to this drug, butoprozine did neither prolong the ventricular monophasic action potential duration nor the ventricular refractory period.

Moquizone is quinazolinone derivative with choleretic and antifibrillatory activity. Oral toxic doses of Moquizone exerted depressant effects, whereas parenteral toxic doses exerted stimulant effects on the central nervous system.

Morazone is is a nonsteroidal anti-inflammatory drug (NSAID), originally developed by the German pharmaceutical company Ravensberg in the 1950s. Morazone was used as a moderately strong analgesic but was discontinued due to high abuse potential

Eclanamine is a nontricyclic antidepressant agent. Down-regulation of beta-adrenergic receptors in the cerebral cortex may be involved in mediating the eclanamine pharmacological effect.

Benzetimide, a muscarinic acetylcholine receptor antagonist that was investigated as an antiparkinson-agent and was studied in the treatment of diarrheas of cattle and calves. Benzetimide is an enantiomer of dexetimide that has been used to treat neuroleptic-induced Parkinsonism.

Betamicin is an aminoglycoside antibiotic

Propipocaine (also known as falicaine) is an aromatic ketone derivative with potent local anaesthetic activity. The toxicity of Propipocaine has been worked out in mice. Given intravenously it is 4 times, and subcutaneously 10 times as toxic as procaine. Falicaine is suitable for surface anaesthesia in a concentration of 0.5 to 1 %. Higher concentrations cause irritation or even necrosis.

Clofenciclan is a dopamine-releasing agent, developed by Boehringer & Soehne in the 1950s for the treatment of Parkinson's disease. Compared to other anti-parkinsonian drugs of the time, clofenciclan lacked peripheral anticholinergic properties and caused pronounced stimulation of the central nervous system.